Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

Abstract Purpose To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival. Methods This retrospective study obtained data from 202...

Full description

Bibliographic Details
Main Authors: Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng, Chao-Yuan Huang
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Prostatic neoplasms
Abiraterone acetate
Enzalutamide
Androgens
Castration
Online Access:https://doi.org/10.1186/s12885-023-10885-4

Internet

https://doi.org/10.1186/s12885-023-10885-4

Similar Items